NY-ESO-1 Polyclonal antibody

NY-ESO-1 Polyclonal Antibody for WB, IF/ICC, IP, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IF/ICC, IP, ELISA

Conjugate

Unconjugated

Cat no : 19521-1-AP

Synonyms

CTAG1A, LAGE2, ESO1, CTAG1, CTAG



Tested Applications

Positive WB detected inhuman testis tissue, HT-1080 cells, NCI-H1299 cells
Positive IP detected inHepG2 cells
Positive IF/ICC detected inHepG2 cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:200-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunofluorescence (IF)/ICCIF/ICC : 1:10-1:100
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

19521-1-AP targets NY-ESO-1 in WB, IF/ICC, IP, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Peptide
Full Name cancer/testis antigen 1A
Calculated Molecular Weight 18 kDa
Observed Molecular Weight 16-25 kDa
GenBank Accession NumberNM_139250
Gene Symbol NY-ESO-1
Gene ID (NCBI) 246100
RRIDAB_10638144
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

CTAG1A, also named as NY-ESO-1, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, CTAG1B, LAGE2B and CT6.1, belongs to the CTAG family.

Protocols

Product Specific Protocols
WB protocol for NY-ESO-1 antibody 19521-1-APDownload protocol
IF protocol for NY-ESO-1 antibody 19521-1-APDownload protocol
IP protocol for NY-ESO-1 antibody 19521-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Cancer Immunol Res

CD8+ T cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance

Authors - Liyan Lao
humanWB

Nat Cancer

The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer.

Authors - Jiang Liu
humanWB

Signal Transduct Target Ther

Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis

Authors - Chuan Yang
humanIF,WB

Cell Death Dis

STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells

Authors - Ling Wang